Phase 2 Trial of Anti-TL1A Monoclonal Antibody Tulisokibart for Ulcerative Colitis.

Date publication

septembre 2024

Journal

The New England journal of medicine

Auteurs

Membres identifiés du Cancéropôle Est :
Pr PEYRIN-BIROULET Laurent

Tous les auteurs :
Sands BE, Feagan BG, Peyrin-Biroulet L, Danese S, Rubin DT, Laurent O, Luo A, Nguyen DD, Lu J, Yen M, Leszczyszyn J, Kempiński R, McGovern DPB, Ma C, Ritter TE, Targan S,

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/39321363

Résumé

Tulisokibart is a tumor necrosis factor-like cytokine 1A (TL1A) monoclonal antibody in development for the treatment of moderately to severely active ulcerative colitis. A genetic-based diagnostic test was designed to identify patients with an increased likelihood of response.

Mots clés

Humans, Colitis, Ulcerative, drug therapy, Female, Male, Adult, Middle Aged, Double-Blind Method, Remission Induction, Tumor Necrosis Factor Ligand Superfamily Member 15, antagonists & inhibitors, Antibodies, Monoclonal, therapeutic use

Référence

N Engl J Med. 2024 09 26;391(12):1119-1129